Tobacco/Nicotine Use Disorder (TUD)
Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.
What is Tobacco/Nicotine Use Disorder (TUD)?
Tobacco Use Disorder (TUD) is characterised by an addictive reliance on nicotine, leading to compulsive tobacco use despite harmful consequences. It is classified as a substance use disorder in the DSM-5.
The pathophysiology involves neuroadaptation within the brain's reward circuitry, particularly the mesolimbic dopamine system. Nicotine reinforces behaviours associated with tobacco consumption through the stimulation of nicotinic acetylcholine receptors.
Symptoms of TUD can include cravings, withdrawal symptoms, and unsuccessful attempts to quit. Behavioral aspects include increased consumption in social settings and the development of tolerance.
Chronic tobacco use is associated with a range of adverse health effects, including cardiovascular disease, respiratory issues, and various types of cancer.
Current Treatments
Standard treatments for TUD include behavioural therapy, nicotine replacement therapies (NRTs) such as patches and gums, and prescription medications like varenicline and bupropion aimed at reducing cravings and withdrawal symptoms.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Tobacco/Nicotine Use Disorder (TUD).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ayahuasca Efficacy shown in clinical studies pointing towards significant reductions in tobacco use. | Large | Moderate | Consistent |
| Ibogaine Demonstrated ability to alleviate withdrawal symptoms commonly associated with nicotine dependence. | Medium | Moderate | Consistent |
| Psilocybin Early-stage studies suggest potential for tobacco cessation, but further research is required. | Small | Low | Inconsistent |
Ayahuasca and Tobacco/Nicotine Use Disorder (TUD)
Ayahuasca, a traditional Amazonian brew, contains DMT and harmaline, which may help in tackling addiction by providing profound emotional insights and facilitating introspection. Users have reported decreased cravings and a re-evaluation of their relationship with tobacco, potentially offering a path towards cessation through a shift in mindset.
Key Insights
- 1
Research suggests that psychedelics like ayahuasca have shown promise in significantly reducing tobacco use among participants in clinical studies.
- 2
Ibogaine has been noted for its unique ability to mitigate withdrawal symptoms, providing an alternative pathway for nicotine cessation.
- 3
Emerging findings indicate that psychedelics can potentially reset addictive pathways in the brain, offering new hope for those struggling with tobacco addiction.
Industrial Landscape
Key industry players include major research institutions like the Beckley Foundation, the Multidisciplinary Association for Psychedelic Studies (MAPS), and various universities that are conducting psychedelics research globally.
Quick Indicators
\"Ongoing clinical evaluations are investigating Tobacco/Nicotine Use Disorder (TUD) as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Tobacco/Nicotine Use Disorder (TUD).